|
The partnership--in which the terms were undisclosed--will expand MeVis' portfolio to include more software products for the detection, diagnosis and intervention of cancers and lung diseases, as well as neurological conditions and could potentially lead to the acquisition of Medis by the MeVis group, according to the companies.
Last updated on January 28, 2010 at 9:12 am EST
|